Total Revenues Increased 14% to $508 Million
GAAP Diluted EPS of $1.47; Adjusted Diluted EPS of $3.67
Received FDA Approval of Sunosi for Excessive Daytime Sleepiness (EDS) Associated withNarcolepsy or Obstructive Sleep Apnea (OSA)
Announced Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and EDS
Launched Xyrem for Pediatric Narcolepsy
DUBLIN, May 7, 2019 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results forthe first quarter of 2019 and reaffirmed 2019 financial guidance.
"In the first quarter of 2019, we delivered strong top- and bottom-line growth and continued our efforts tobring innovative and life-changing medicines to patients, with FDA approval of Sunosi for EDS associated with narcolepsy or OSA, launch of Xyrem in pediatric narcolepsy and announcement of positive top-line results from our Phase 3 study of JZP-258,” said Bruce Cozadd, chairman and chief executive officer
of Jazz Pharmaceuticals. “As the year progresses, we are continuing to invest in our business to support the successful launch of Sunosi in the U.S. and pre-launch activities in the EU, to generate data for our existing products and to fuel further advancement and diversification of our pipeline.”
The full press release can be found by using the following link:
http://www.bsx.com/CompanyDocuments/1099938868/1Q19%20FinancialPR%20FINAL.pdf
Disclaimer and Privacy Policy Complaints Policy
Copyright © 2024 by Bermuda Stock Exchange. All rights reserved!
Questions or requests for information can be emailed to info@bsx.com